Bayer to Advance Two First-of-its-Kind Investigational Cell and Gene Therapies for Parkinson’s Disease

Bayer to Advance Two First-of-its-Kind Investigational Cell and Gene Therapies for Parkinson’s Disease
Parkinson's disease is the most common neurodegenerative movement disorder. It impacts more than 10 million people worldwide Bayer is pursuing a two-pronged approach ... read more
Source: Bing NewsPublished on 2021-06-08